Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Sakai City, Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), M. Kolb (Hamilton, Ontario, Canada), D. Koschel (Coswig, Germany), T. Moua (Rochester, MN, United States of America), S. Stowasser (Ingelheim am Rhein, Germany), R. Goeldner (Biberach, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America)
Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Sakai City, Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), M. Kolb (Hamilton, Ontario, Canada), D. Koschel (Coswig, Germany), T. Moua (Rochester, MN, United States of America), S. Stowasser (Ingelheim am Rhein, Germany), R. Goeldner (Biberach, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America). Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial. 4578
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: